参考文献/References:
［1］ CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［2］ GROSS G,WAKS T,ESHHAR Z.Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity［J］.Proc Natl Acad Sci USA,1989,86(24):10024-10028.
［3］ DAI H,WANG Y,LU X,et al.Chimeric antigen receptors modified T-cells for cancer therapy［J］.J Natl Cancer Inst,2016,108(7)：439.
［4］ BEATSON R,TAJADURA-ORTEGA V,ACHKOVA D,et al.The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9［J］.Nat Immunol,2016,17(11):1273-1281.
［5］ BATLEVI C L,MATSUKI E,BRENTJENS R J,et al.Novel immunotherapies in lymphoid malignancies［J］.Nat Rev Clin Oncol,2016,13(1):25-40.
［6］ KLOSS C C,CONDOMINES M,CARTELLIERI M,et al.Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells［J］.Nat Biotechnol,2013,31(1):71-75.
［7］ MUNIAPPAN A,BANAPOUR B,LEBKOWSKI J,et al.Ligand-mediated cytolysis of tumor cells:use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes［J］.Cancer Gene Ther,2000,7(1):128-134.
［8］ ZUO B L,YAN B,ZHENG G X,et al.Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor［J］.Cancer Immunol Immunother,2018,67(3):393-401.
［9］ KUDO K,IMAI C,LORENZINI P,et al.T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing［J］.Cancer Res,2014,74(1):93-103.
［10］ SENTMAN C L,MEEHAN K R.NKG2D CARs as cell therapy for cancer［J］.Cancer J,2014,20(2):156-159.
［11］ DUSTIN M L,DEPOIL D.New insights into the T cell synapse from single molecule techniques［J］.Nat Rev Immunol,2011,11(10):672-684.
［12］ PULE M A,STRAATHOF K C,DOTTI G,et al.A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells［J］.Mol Ther,2005,12(5):933-941.
［13］ BEZBRADICA J S,MEDZHITOV R.Role of ITAM signaling module in signal integration［J］.Curr Opin Immunol,2012,24(1):58-66.
［14］ ZHAO Z,CONDOMINES M,VAN DER STEGEN S,et al.Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells［J］.Cancer Cell,2015,28(4):415-428.
［15］ HOMBACH A A,RAPPL G,ABKEN H.Arming cytokine-induced killer cells with chimeric antigen receptors:CD28 outperforms combined CD28-OX40 "super-stimulation"［J］.Mol Ther,2013,21(12):2268-2277.
［16］ GRECO R,OLIVEIRA G,STANGHELLINI M T,et al.Improving the safety of cell therapy with the TK-suicide gene［J］.Front Pharmacol,2015,6:95.
［17］ GARGETT T,BROWN M P.The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target,off-tumor toxicities of chimeric antigen receptor T cells［J］.Front Pharmacol,2014,5:235.
［18］ DI STASI A,TEY S K,DOTTI G,et al.Inducible apoptosis as a safety switch for adoptive cell therapy［J］.N Engl J Med,2011,365(18):1673-1683.
［19］ WANG X,CHANG W C,WONG C W,et al.A transgene-encoded cell surface polypeptide for selection,in vivo tracking,and ablation of engineered cells［J］.Blood,2011,118(5):1255-1263.
［20］ FEDOROV V D,THEMELI M,SADELAIN M.PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses［J］.Sci Transl Med,2013,5(215):172-215.
［21］ ROYBAL K T,RUPP L J,MORSUT L,et al.Precision tumor recognition by T cells with combinatorial antigen-sensing circuits［J］.Cell,2016,164(4):770-779.
［22］ RODGERS D T,MAZAGOVA M,HAMPTON E N,et al.Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies［J］.Proc Natl Acad Sci USA,2016,113(4):E459-E468.
［23］ MA J S,KIM J Y,KAZANE S A,et al.Versatile strategy for controlling the specificity and activity of engineered T cells［J］.Proc Natl Acad Sci USA,2016,113(4):E450-E458.
［24］ BEATTY G L,HAAS A R,MAUS M V,et al.Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies［J］.Cancer Immunol Res,2014,2(2):112-120.
［25］ BROWN C E,BADIE B,BARISH M E,et al.Bioactivity and safety of IL13 R alpha2-redirected chimeric antigen receptor CD8+T cells in patients with recurrent glioblastoma［J］.Clin Cancer Res,2015,21(18):4062-4072.
［26］ ERTL H C,ZAIA J,ROSENBERG S A,et al.Considerations for the clinical application of chimeric antigen receptor T cells:observations from a Recombinant DNA Advisory Committee Symposium held June 15,2010［J］.Cancer Res,2011,71(9):3175-3181.
［27］ CRADDOCK J A,LU A,BEAR A,et al.Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b［J］.J Immunother,2010,33(8):780-788.
［28］ DI STASI A,DE ANGELIS B,ROONEY C M,et al.T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model［J］.Blood,2009,113(25):6392-6402.
［29］ CHINNASAMY D,YU Z,KERKAR S P,et al.Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice［J］.Clin Cancer Res,2012,18(6):1672-1683.
［30］ CARUANA I,SAVOLDO B,HOYOS V,et al.Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes［J］.Nat Med,2015,21(5):524-529.
［31］ WANG X,RIVIERE I.Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies［J］.Cancer Gene Ther,2015,22(2):85-94.
［32］ CHEUNG A S,ZHANG D,KOSHY S T,et al.Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells［J］.Nat Biotechnol,2018,36(2):160-169.
［33］ SOCKOLOSKY J T,TROTTA E,PARISI G,et al.Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes［J］.Science,2018,359(6379):1037-1042.
［34］ TORIKAI H,REIK A,LIU P Q,et al.A foundation for universal T-cell based immunotherapy:T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR ［J］.Blood,2012,119(24):5697-5705.
［35］ EYQUEM J,MANSILLA-SOTO J,GIAVRIDIS T,et al.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection［J］.Nature,2017,543(7643):113-117.
［36］ FOSTER A E,DOTTI G,LU A,et al.Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor［J］.J Immunother,2008,31(5):500-505.
［37］ ZHANG T,SENTMAN C L.Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells ［J］.Cancer Res,2011,71(6):2066-2076.
［38］ LONG A H,HASO W M,SHERN J F,et al.4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors［J］.Nat Med,2015,21(6):581-590.
［39］ PEGRAM H J,LEE J C,HAYMAN E G,et al.Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning［J］.Blood,2012,119(18):4133-4141.
［40］ LEEN A M,SUKUMARAN S,WATANABE N,et al.Reversal of tumor immune inhibition using a chimeric cytokine receptor［J］.Mol Ther,2014,22(6):1211-1220.
［41］ PROSSER M E,BROWN C E,SHAMI A F,et al.Tumor PD-L1 co-stimulates primary human CD8+cytotoxic T cells modified to express a PD1:CD28 chimeric receptor［J］.Mol Immunol,2012,51(3/4):263-272.
［42］ JOHN L B,KERSHAW M H,DARCY P K.Blockade of PD-1 immunosuppression boosts CAR T-cell therapy［J］.Oncoimmunology,2013,2(10):e26286.